Ministry of Health – Page 6 – Communicable Diseases Research

Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients

Public Health

Published on 2022-02-222022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, COVID19(2023년), SARS,

Association between living in municipalities with high crowding conditions and poverty and mortality from COVID-19 in Mexico

Research Article

Published on 2022-02-222022-10-28
Journal: PLoS ONE [Category] COVID-19, COVID19(2023년), MERS, SARS,

[키워드] 95% CI acute respiratory syndrome Affect age Analysis association Characteristics collected condition coronavirus COVID-19 COVID-19 pandemic death develop disease elevated examined food insecurity frailty Health Health Service Healthcare systems higher risk illiteracy implication increased risk increased the risk individual information less Ministry of Health Mortality objective Occurrence outcome pandemic Patient platform Policy populations positive random effect reduce regression models Result risk SARS-CoV-2 subject System tested the patient viral respiratory World Health Organization
[DOI] 10.1371/journal.pone.0264137 PMC 바로가기 [Article Type] Research Article

Control Centre for Intensive Care as a Tool for Effective Coordination, Real-Time Monitoring, and Strategic Planning During the COVID-19 Pandemic

Viewpoint

Published on 2022-02-162022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, COVID19(2023년), MERS, SARS,

Return to Play after SARS-CoV-2 Infection in Competitive Athletes of Distinct Sport Disciplines in Italy: A FMSI (Italian Federation of Sports Medicine) Study

Article

Published on 2022-02-152022-10-30
Journal: Journal of Cardiovascular Development and Disease [Category] COVID-19,

[키워드] age approach Asymptomatic athlete Athletes cardiac cardiac complication cardiac injuries center complications COVID-19 COVID-19 infection Critical Discipline disease ECG echocardiographic echocardiographic finding Electrocardiography enrolled event Federation females imaging Italian male manifested Medicine mild symptoms Ministry of Health moderate MRI multicenter Myocardial myocarditis Nasopharyngeal swab performed physical activity Premature Prevalence protocol representing resonance return return to play risk stratification Safe SARS-CoV-2 SARS-COV-2 infection severe symptoms sport Symptom symptomatic tested total population ventricular ventricular arrhythmia was performed were recorded worsened
[DOI] 10.3390/jcdd9020059 PMC 바로가기 [Article Type] Article

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Ad26.COV2.S 백신 수용자에서 동종 대 이종 부스트의 차등 면역원성

Article

Published on 2022-02-112022-09-11
Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus Adenovirus Vector Antiviral antiviral immunity BNT162b2 boost breadth cellular immune responses cellular immunity ChAdOx1 ChAdOx1 nCoV-19 college coronavirus disease Coronavirus disease 2019 COV2.S COVID-19 dose ENhance feature Heterologous heterologous immunity heterologous vaccine homologous homologous or heterologous humoral immune responses immunological immunological parameter individual individuals knowledge lack Medical Research Council Ministry of Health mRNA of BNT162b2 offered protection pump quantity recipient second dose Singapore single dose small sample size SMD specific antibodies spike-specific antibodies Spike-specific antibody Support supported T cell T cells Trustee utilization vaccination Vaccine Vaccines
[DOI] 10.1016/j.medj.2021.12.004 PMC 바로가기 [Article Type] Article

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종

Clinical Trial

Published on 2022-02-052022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine
[DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial

Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine

Article

Published on 2022-02-032022-10-28
Journal: Vaccines [Category] COVID-19,

COVID-19 in Saudi Arabia: An Overview

Public Health

Published on 2022-02-022022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, COVID19(2023년), MERS, SARS,

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

COVID-19(DisCoVeRy)로 입원한 환자의 치료를 위한 렘데시비르 + 표준 치료 대 표준 치료 단독: 3상, 무작위, 대조, 공개 시험

Clinical Trial

Published on 2022-02-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] Fulltext, MERS, 임상, 치료법, 치료제,

[키워드] Abstract activities activity acute respiratory distress acute respiratory distress syndrome adaptive Administered Adult patient Adult patients Analysis antiviral efficacy assigned Bacterial infection Belgium block Breastfeeding Chronic kidney disease clinical clinical benefit Clinical efficacy clinical evidence Clinical research clinical status Combination Commission computer-generated conducted control group Controlled trial COVID-19 criteria death development discharged distribution elevated elevated liver enzymes eligible enrolled Europe European evaluate evidence of exclusion criteria extracorporeal membrane oxygenation followed by France French group Health care hepatorenal syndrome high flow oxygen devices hospital hospitalised Hydroxychloroquine Inclusion indication Innovation intention-to-treat population interferon interferon beta Interferon beta-1a intravenous intravenous infusion Invasive mechanical ventilation investigators Kidney disease laboratory-confirmed SARS-CoV-2 infection limitation liver enzymes Lopinavir Lopinavir-ritonavir Luxembourg material Ministry of Health modified intention-to-treat multicentre no significant difference non-invasive ventilation not significant Occurrence Odds ratio once daily one health Open-label Ordinal Scale oxygen oxygen supplementation oxygen support participant Patient Phase 3 Pneumonia Portugal Pregnancy Primary outcome random assignment randomisation randomised Randomly receive Regional Registered Remdesivir required requiring supplemental oxygen respiratory distress ribavirin Ritonavir Safety SARS-CoV-2 SARS-COV-2 infection Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale Severity of disease Sponsor Standard of care stratified supplemental oxygen Support symptomatic syndrome the WHO translation Treatment treatment group treatment groups Trial Tumor union ventilator were excluded WHO ordinal scale with COVID-19
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial

Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study

Research article

Published on 2022-02-012022-10-05
Journal: The Lancet Regional Health - Europe [Category] 유전자 메커니즘,

[키워드] addition administration age anti-S anti-S antibody Anti-spike antibody Antibody titre Antiretroviral therapy ART CD4+ T cell Cell Cohort cohort study collected Combination COVID-19 COVID-19 emergency detectable enrolled finding funding HIV HIV infection humoral immune response individual Italian male median Ministry of Health mRNA-1273 mRNA-1273 vaccine neutralising antibody activity not affected Outpatient performed plasma PLWHIV powerful tool Primary outcome produced prospective cohort robust SARS-CoV-2 SARS-CoV-2 pandemic sera stratified supported titre two-dose regimen vaccination vaccination schedule Viral load with COVID-19 with HIV
[DOI] 10.1016/j.lanepe.2021.100287 [Article Type] Research article